(Q38200765)

30 August 2017

title

Strategies for the management of adverse events associated with mTOR inhibitors (English)

1 reference

30 August 2017

Bruce Kaplan

1

1 reference

30 August 2017

Yasir Qazi

series ordinal

2

1 reference

30 August 2017

Jason R Wellen

series ordinal

3

1 reference

30 August 2017

publication date

12 March 2014

1 reference

30 August 2017

published in

Transplantation Reviews

1 reference

30 August 2017

volume

28

1 reference

30 August 2017

issue

3

1 reference

30 August 2017

page(s)

126-133

1 reference

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Targeting mTOR pathways in human malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

The podocyte as a direct target of immunosuppressive agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Inhibition of MTOR disrupts autophagic flux in podocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Anaemia, microcytosis and sirolimus--is iron the missing link?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Hypertension after kidney transplant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Low-dose oral sirolimus and the risk of menstrual-cycle disturbances and ovarian cysts: analysis of the randomized controlled SUISSE ADPKD trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Sirolimus impairs gonadal function in heart transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Wound events in kidney transplant patients receiving de novo everolimus: a pooled analysis of three randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

mTOR inhibitor-associated dermatologic and mucosal problems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Management of mTOR inhibitor side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Clinical presentation and management of mTOR inhibitor-associated stomatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Surgical wound complications after heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Early use of mammalian target of rapamycin inhibitors is an independent risk factor for incisional hernia development after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Defects in skin gamma delta T cell function contribute to delayed wound repair in rapamycin-treated mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Accelerated wound healing by mTOR activation in genetically defined mouse models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Targeting risk factors for impaired wound healing and wound complications after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Management of side effects of sirolimus therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Clinical recommendations for the use of everolimus in heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Intraoperative placing of drains decreases the incidence of lymphocele and deep vein thrombosis after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Adverse events associated with mTOR inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Laparoscopic incisional hernia repair after solid-organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Bacterial clearance of biologic grafts used in hernia repair: an experimental study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Human acellular dermal matrix for ventral hernia repair reduces morbidity in transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Sirolimus-associated lymphoedema: eight new cases and a proposed mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

The metabolic effects of cyclosporin and tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Sirolimus is associated with new-onset diabetes in kidney transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Proteinuria in kidney transplant recipients: prevalence, prognosis, and evidence-based management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Is proteinuria reversible, after withdrawal of mammalian target of rapamycin inhibitors?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

mToR inhibitors-induced proteinuria: mechanisms, significance, and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

The mTOR-inhibitor rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

mTOR inhibitor-associated proteinuria in kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Urine metabolites reflect time-dependent effects of cyclosporine and sirolimus on rat kidney function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Everolimus and sirolimus in combination with cyclosporine have different effects on renal metabolism in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

A drug safety evaluation of everolimus in kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Sirolimus Prolongs Recovery from Delayed Graft Function After Cadaveric Renal Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

The detrimental effect of poor early graft function after laparoscopic live donor nephrectomy on graft outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Sirolimus-associated pulmonary toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Severe everolimus-associated pneumonitis in a renal transplant recipient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Sirolimus-induced pneumonitis complicated by pentamidine-induced phospholipidosis in a renal transplant recipient: a case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Posttransplant anemia: the role of sirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Sirolimus is associated with impaired hematopoiesis in heart transplant patients? A retrospective analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Prevalence of anemia in renal transplant patients: results from MOST, an observational trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

mTOR inhibition and erythropoiesis: microcytosis or anaemia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Sirolimus-Associated Testicular Toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Testosterone concentrations and sirolimus in male renal transplant patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

High prevalence of ovarian cysts in premenopausal women receiving sirolimus and tacrolimus after clinical islet transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

Alterations of the female reproductive system in recipients of islet grafts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.03.002

10.1016/J.TRRE.2014.03.002

7 January 2021

Identifiers

DOI

1 reference

30 August 2017

1 reference